These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36644856)

  • 21. Identification of Potent Acetylcholinesterase Inhibitors as New Candidates for Alzheimer Disease via Virtual Screening, Molecular Docking, Dynamic Simulation, and Molecular Mechanics-Poisson-Boltzmann Surface Area Calculations.
    Chennai HY; Belaidi S; Bourougaa L; Ouassaf M; Sinha L; Samadi A; Chtita S
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combinatorial approach to screen structurally diverse acetylcholinesterase inhibitory plant secondary metabolites targeting Alzheimer's disease.
    Choudhir G; Sharma S; Hariprasad P
    J Biomol Struct Dyn; 2022; 40(22):11705-11718. PubMed ID: 34351840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy.
    Shamsi A; Anwar S; Mohammad T; Alajmi MF; Hussain A; Rehman MT; Hasan GM; Islam A; Hassan MI
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32443670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, biological activities, and evaluation of molecular docking-dynamics studies of new thiosemicarbazones that may be effective against Alzheimer's disease.
    Conger N; Osmaniye D; Sağlık BN; Levent S; Ozkay Y; Kaplancıklı ZA
    J Mol Recognit; 2023 Dec; 36(12):e3059. PubMed ID: 37723924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): Molecular docking and saturation transfer difference NMR (STD-NMR).
    Bacalhau P; San Juan AA; Goth A; Caldeira AT; Martins R; Burke AJ
    Bioorg Chem; 2016 Aug; 67():105-9. PubMed ID: 27317888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
    Hu XM; Dong W; Cui ZW; Gao CZ; Yu ZJ; Yuan Q; Min ZL
    J Mol Model; 2018 Jun; 24(7):151. PubMed ID: 29869722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lead Identification Through
    Agarwal D; Kumar S; Ambatwar R; Bhanwala N; Chandrakar L; Khatik GL
    Cent Nerv Syst Agents Med Chem; 2024; 24(2):219-242. PubMed ID: 38288823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, biological evaluation and molecular modeling studies of modulated benzyloxychalcones as potential acetylcholinesterase inhibitors.
    Abdalla Ali A; Mhamad SA; Hasan AH; Ahmad I; Abdullah SA; Jamil S; Patel H; Murugesan S; Jamalis J
    J Biomol Struct Dyn; 2024 Apr; 42(7):3604-3615. PubMed ID: 37293930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
    Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of quinazolinone and vanillin acrylamide hybrids as multi-target directed ligands against Alzheimer's disease and mechanistic insights into their binding with acetylcholinesterase.
    Yelamanda Rao K; Jeelan Basha S; Monika K; Naidu Gajula N; Sivakumar I; Kumar S; Vadde R; Aramati BMR; Subramanyam R; Damu AG
    J Biomol Struct Dyn; 2023 Dec; 41(20):11148-11165. PubMed ID: 37098803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
    Son M; Park C; Rampogu S; Zeb A; Lee KW
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetylcholinesterase inhibition of Alzheimer's disease: identification of potential phytochemicals and designing more effective derivatives to manage disease condition.
    Koly HK; Sutradhar K; Rahman MS
    J Biomol Struct Dyn; 2023; 41(22):12532-12544. PubMed ID: 36651199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioassays guided isolation of berberine from Berberis lycium and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with insilico molecular docking.
    Ismail H; Khalid D; Waseem D; Ijaz MU; Dilshad E; Haq IU; Bhatti MZ; Anwaar S; Ahmed M; Saleem S
    PLoS One; 2023; 18(11):e0286349. PubMed ID: 37910530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular interaction of anti-cancer ligands with human brain acetylcholinesterase.
    Shakil S
    J Biomol Struct Dyn; 2022 Mar; 40(5):2254-2263. PubMed ID: 33089743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the Binding Pattern of Geraniol with Acetylcholinesterase through In Silico Docking, Molecular Dynamics Simulation, and In Vitro Enzyme Inhibition Kinetics Studies.
    Iqbal D; Khan MS; Waiz M; Rehman MT; Alaidarous M; Jamal A; Alothaim AS; AlAjmi MF; Alshehri BM; Banawas S; Alsaweed M; Madkhali Y; Algarni A; Alsagaby SA; Alturaiki W
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.
    Wang L; Wang Y; Tian Y; Shang J; Sun X; Chen H; Wang H; Tan W
    Bioorg Med Chem; 2017 Jan; 25(1):360-371. PubMed ID: 27856236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.
    Kiametis AS; Silva MA; Romeiro LA; Martins JB; Gargano R
    J Mol Model; 2017 Feb; 23(2):67. PubMed ID: 28185116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metal based donepezil analogues designed to inhibit human acetylcholinesterase for Alzheimer's disease.
    Junaid M; Islam N; Hossain MK; Ullah MO; Halim MA
    PLoS One; 2019; 14(2):e0211935. PubMed ID: 30785927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multitargeted Molecular Docking and Dynamic Simulation Studies of Bioactive Compounds from
    Mirza FJ; Zahid S; Amber S; Sumera ; Jabeen H; Asim N; Ali Shah SA
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
    Kumar S; Chowdhury S; Kumar S
    BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.